PCI‪s Tredegar Site Announces Significant Expansion of Analytical Laboratories at its Center of Excellence for Contained Manufacturing
March 19, 2018 – Manufacturing and Packing –
Philadelphia, USA- March 19, 2018. Global pharmaceutical
outsourcing services provider PCI Pharma Services (PCI) is pleased to announce
a laboratory expansion at its site in Tredegar, Wales, UK.
The Tredegar facility is PCIís development and manufacturing
Center of Excellence with specialist expertise in the processing of highly
potent molecules. The site has undergone significant investments over recent
years; this latest project ensures analytical capacity and capability to
service increasing customer demand.
The investment will
see PCIís laboratory increase its analyst headcount by approximately 60 percent
and increase its High-Performance Liquid Chromatography (HPLC) capacity in
excess of 20 percent, in addition to tripling its capacity for sample receipt.
The layout design of the facility incorporates state-of-the-art Lean
philosophies and optimized safety, combined with leading ergonomic principles,
to deliver enhanced throughput and additional efficiency improvements.
Since launching its
contained manufacturing facility utilizing the latest in containment technology
at Tredegar, the site has seen significant growth in its global customer base.
This latest project will ensure that PCI is able to service both existing and
potential new clients, as well as offering a project initiation in terms of
analytical transfer within 4-6 weeks.
The site offers a
true Center of Excellence for the development and manufacturing of
pharmaceutical products in a variety of dosage forms and has over 30 years of
experience in the specialist handling of potent molecules. Investment in
state-of-the-art contained equipment, combined with the creation of a ëPotent
Passportí philosophy to identify the specific handling requirements for every
Highly Potent Active Pharmaceutical Ingredient (HPAPI) project, defines PCI as
a market leader within this space. Contained technology includes Xcelodose
micro-dosing for early stage development drug-in-capsule (DIC), fluid bed
granulation and roller compaction for products sensitive to heat and moisture.
Commenting on the
expansion, PCI Senior Vice President, International, Richard Yarwood said:
‘Expansion of our laboratory services is an important program for the Tredegar
site. Speed to market is of critical importance to our clients. We pride
ourselves on continually improving our service for both existing and potential
new clients and our analytical service is integral from the early stages of
analytical development through to commercial launch and the associated annual
stability testing.’
He continued ‘Among
our many key strengths is our ability to on-board projects faster than our
competitors. This additional footprint will ensure we are able to continue to
offer this speed of project initiation addressing customer need.’
To find out more
about PCI please visit www.pciservices.com.
About PCI
The global healthcare
industry trusts PCI for the drug development solutions that increase their
productsí speed to market and opportunities for commercial success. Only PCI
brings the proven experience that comes with more than 50 successful product
launches a year and over four decades in the healthcare business. Leading
technology and continued investment enables us to address global development
needs throughout the product life cycle ó from Phase I clinical trials through
commercialization and ongoing supply. Our clients view us as an extension of
their business and a collaborative partner, with the shared goal of improving patientsí
lives. For more information, please visit www.pciservices.comor follow us on
Twitter at @PCI_Social.
Contact
Chantel Richman / Carrie Lowe at BECG
chantel.richman@becg.com/ carrie.lowe@becg.com
T: +44 (0)20 3697
0158 / +44 (0)1962 893 913
